These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
392 related items for PubMed ID: 37199669
1. Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa. Wang L, Zhang X, Zhou X, Yang F, Guo Q, Wang M. Microbiol Spectr; 2023 Jun 15; 11(3):e0093223. PubMed ID: 37199669 [Abstract] [Full Text] [Related]
3. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa. Zhang Y, Zhao J, Han J, Fan Y, Xiong Z, Zou X, Li B, Liu X, Li Z, Lu B, Cao B. Microbiol Spectr; 2022 Apr 27; 10(2):e0274021. PubMed ID: 35315696 [Abstract] [Full Text] [Related]
4. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021). Sader HS, Mendes RE, Arends SJR, Carvalhaes CG, Shortridge D, Castanheira M. Int J Antimicrob Agents; 2023 Apr 27; 61(4):106744. PubMed ID: 36738849 [Abstract] [Full Text] [Related]
8. Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021. Li H, Oliver A, Shields RK, Kamat S, Stone G, Estabrook M. Antimicrob Agents Chemother; 2024 Oct 08; 68(10):e0067024. PubMed ID: 39254297 [Abstract] [Full Text] [Related]
10. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital. Weber C, Schultze T, Göttig S, Kessel J, Schröder A, Tietgen M, Besier S, Burbach T, Häussler S, Wichelhaus TA, Hack D, Kempf VAJ, Hogardt M. Microbiol Spectr; 2022 Oct 26; 10(5):e0169722. PubMed ID: 36190424 [Abstract] [Full Text] [Related]
11. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa. Delgado-Valverde M, Portillo-Calderón I, Alcalde-Rico M, Conejo MC, Hidalgo C, Del Toro Esperón C, Pascual Á. Eur J Clin Microbiol Infect Dis; 2024 Mar 26; 43(3):445-457. PubMed ID: 38157139 [Abstract] [Full Text] [Related]
12. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam. Di Pilato V, Principe L, Andriani L, Aiezza N, Coppi M, Ricci S, Giani T, Luzzaro F, Rossolini GM. Clin Microbiol Infect; 2023 Apr 26; 29(4):537.e1-537.e8. PubMed ID: 36414199 [Abstract] [Full Text] [Related]
18. Assessment of the In Vitro Activities of Ceftolozane/Tazobactam and Ceftazidime/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Clinical Isolates at Montpellier University Hospital, France. Viala B, Zaidi FZ, Bastide M, Dumont Y, Le Moing V, Jean-Pierre H, Godreuil S. Microb Drug Resist; 2019 Nov 26; 25(9):1325-1329. PubMed ID: 31225764 [Abstract] [Full Text] [Related]